A ‘co-promotion’ agreement has been signed aiming to bring synergy in the areas of alleviating severe disease conditions like cancer, ophthalmology and neurology in Bangladesh.
The signing ceremony took place at the Radisson Blu Hotel in Dhaka city on Sunday (November 12, 2023).
F. Hoffmann-La Roche, Switzerland, a globally leading research-based innovative pharmaceutical company; and Radiant Pharmaceuticals Limited, one of the top-ten manufacturers of pharmaceutical products in Bangladesh and a leading importer of specialized lifesaving medicines, signed the agreement.
Building upon their successful existing partnership, Roche & Radiant have collaborated to introduce innovative ‘Co-Promotion’ - a synchronized promotional strategy, where both companies will work hand in hand to raise awareness and update healthcare professionals and patients about the benefits and advancements of Roche's oncology portfolio in Bangladesh.
Through this unique partnership, both companies aim to maximize their expertise and resources to significantly enhance patient care in Bangladesh.
Adriano Treve, Area Head of Roche's Central Eastern Europe, Turkey, Russia, and Indian Subcontinent (CEETRIS) graced the event with his presence.
In his speech, he emphasized the significance of this collaboration, highlighting the potential to unlock new avenues for the accessibility of high-quality innovative treatments to the people of Bangladesh.
Chairman of Radiant Pharmaceuticals Md. Nasser Shahrear Zahedee also attended the event.
He expressed confidence in this novel collaboration as a milestone for the Bangladesh pharmaceuticals industry.
With a focus on mutual trust and cooperation, Zahedee envisioned a future where the pharmaceutical industry will thrive benefiting the nation and its citizens.
Mark Heeb, Country Manager of Roche Bangladesh and Lt. Gen. Sina Ibn Jamali, Managing Director & CEO of Radiant Pharmaceuticals Limited, were present at the event, among others.
